hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06300099 id: AZAST/Research/52/20-Jan-2024 briefTitle: Dexamethasone Versus Dexmedetomidine as Adjuncts to Serratus Anterior Plane Block overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2024-10-01 date: 2024-03-08 date: 2024-03-12 name: Al-Azhar University class: OTHER briefSummary: Modified radical mastectomy is the most commonly performed surgical approach for breast cancer. The procedure enables surgeons to remove the main tumor mass, adjacent glandular tissue and regional lymph nodes. Moreover, it provides a cosmetic outcome that clearly surpasses the standard radical mastectomy and allows subsequent breast reconstruction with favorable results.
The present randomized study aims to compare the postoperative analgesic effects of dexamethasone and dexmedetomidine as adjuncts to serratus anterior plane block in women undergoing modified radical mastectomy. conditions: Breast Cancer studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 126 type: ESTIMATED name: Dexamethasone name: Dexmedetomidine measure: postoperative visual assessment scale for pain. sex: FEMALE minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06300086 id: NUDGE-CKD briefTitle: Nationwide Utilization of Danish Government Electronic Letter System for Increasing Guideline-directed Medical Therapy in Chronic Kidney Disease acronym: NUDGE-CKD overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2034-10-01 date: 2024-03-08 date: 2024-03-08 name: Tor Biering-Sørensen class: OTHER briefSummary: Kidney Disease Improving Global Outcomes (KDIGO) has recently updated the Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). This update follows large placebo-controlled randomized trials, which established sodium-glucose cotransporter 2 inhibitors (SGLT2i) as an additional treatment option to reduce the risk of progression to kidney failure and cardiovascular disease in patients with CKD, both with and without diabetes or albuminuria. As a result, SGLT2i is now recommended to a broad range of CKD patients by KDIGO, along with established medical therapies such as renin-angiotensin system inhibition (RASi). Despite the significant adverse consequences of CKD and substantial evidence supporting guideline-directed medical therapy (GDMT) to improve patient outcomes, awareness of CKD among patients and providers remains disproportionately low. Innovative solutions are needed to increase awareness of CKD. Such a solution could potentially be the use of electronic nudge letters delivered to patients with CKD and their general practitioners (GPs) that highlight the importance of GDMT and inform them of updated guidelines.
nctId: NCT06300073 id: AB-360-001-2022 briefTitle: Plaque Removal Efficacy of a U-Shaped Sonic Power Toothbrush in Children overallStatus: COMPLETED date: 2023-02-14 date: 2023-02-17 date: 2023-02-17 date: 2024-03-08 date: 2024-03-08 name: Lander Enterprises, LLC class: INDUSTRY briefSummary: The objective of this single-use, examiner blinded, randomized, two-period, cross-over, IRB-approved clinical study is to evaluate the safety and plaque removal efficacy of AutoBrush®, a new children's 360° sonic toothbrush, compared to a marketed children's manual toothbrush. conditions: Dental Plaque studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: single-use, randomized, two-period, cross-over study primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Examiner and data recorder will not have access to the room for test materials dispensing and instructions. whoMasked: OUTCOMES_ASSESSOR count: 22 type: ACTUAL name: Experimental: U-shaped Power Toothbrush name: Placebo Comparator: Soft Manual Toothbrush measure: Within-Treatment Whole-Mouth Differences (vs Baseline) - Plaque removal Mean Change from baseline (pre-brushing to post-brushing) in plaque score after single supervised use based on all tooth surfaces of the whole mouth. sex: ALL minimumAge: 5 Years maximumAge: 8 Years stdAges: CHILD facility: Salus Research, Inc city: Fort Wayne state: Indiana zip: 46825 country: United States lat: 41.1306 lon: -85.12886 hasResults: False
nctId: NCT06300060 id: REB23-1161 briefTitle: Synbiotic Supplementation in Cyclists overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-02-01 date: 2025-02-01 date: 2024-03-08 date: 2024-03-08 name: University of Calgary class: OTHER name: Lallemand Health Solutions briefSummary: The goal of this clinical trial is to assess the efficacy of a synbiotic blend on exercise performance and other exercise parameters in trained adult cyclists. It is hypothesized that those taking the synbiotic blend will have improved endurance exercise performance.
The primary objective is to assess the impact of a synbiotic on 20km distance trial performance in 36 cyclists. Secondary objectives include assessing the impact of the synbiotic on exercise metabolism, body composition, gastrointestinal and immune health. conditions: Exercise Endurance studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel arm. Single-site, double-blinded, placebo-controlled trial. primaryPurpose: SUPPORTIVE_CARE masking: QUADRUPLE maskingDescription: The synbiotic and placebo are both powders identical in taste and appearance and are equally dissolvable in cold water. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: Synbiotic name: Placebo measure: Change in endurance exercise performance measured during a 20km cycling distance trial measure: Change in maximal oxygen consumption (V̇O2max) measured during a Step-Ramp-Step Test measure: Change in peak power output (PPO) measured during a Step-Ramp-Step Test measure: Change in power output corresponding to the gas exchange threshold (GET) and respiratory compensation point (RCP) measure: Change in time to exhaustion measured during a cycling session at 85% of the peak power output measure: Change in fat and carbohydrate oxidation measured during exercise sessions measure: Change in blood lactate concentration measured via pinprick capillary blood test measure: Change in body composition measured by dual energy X-ray absorptiometry (DXA) measure: Change in intestinal permeability markers measured in serum measure: Change in cytokines measure: Change in gastrointestinal symptoms measured by self-report measure: Change in fecal SCFA concentration measured by gas chromatography measure: Synbiotic strains quantification measured by qPCR in fecal matter measure: Change in fecal microbiota composition measure: Incidence of adverse events sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: University of Calgary city: Calgary state: Alberta zip: T2N 1N4 country: Canada name: Raylene A Reimer, PhD, RD role: CONTACT phone: 403-220-8218 email: reimer@ucalgary.ca lat: 51.05011 lon: -114.08529 hasResults: False
nctId: NCT06300047 id: REB23-0679 briefTitle: Diabetes Transition Coordinator Study overallStatus: ENROLLING_BY_INVITATION date: 2024-04-01 date: 2028-12-31 date: 2028-12-31 date: 2024-03-08 date: 2024-03-08 name: University of Calgary class: OTHER name: Juvenile Diabetes Research Foundation name: Canadian Institutes of Health Research (CIHR) briefSummary: The goal of this interventional study is to assess the effects and evaluate the implementation of a pediatric to adult care transition intervention in youth with T1D on clinical, patient-reported, and implementation outcomes, including an economic analysis.
Researchers will compare a pre-intervention cohort to evaluate the impact of the transition coordinator intervention. conditions: Type 1 Diabetes studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: The usual care group is defined as the group who receives usual care and serves as the control group. This group is defined prior to the implementation of the intervention. We include a two month wash out period between our two groups to avoid care providers 'holding on' to patients they feel may benefit from the intervention primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 324 type: ESTIMATED name: Non-Medical Transition Coordinator measure: Lost to Followup measure: Patient Reported Outcome Survey 1 measure: Patient Reported Outcome Survey 2 measure: Patient Reported Outcome Survey 3 measure: Clinical Outcome 1 measure: Clinical Outcome 2 measure: Clinical outcome 3 measure: Clinical outcome 4 measure: Clinical Outcome 5 measure: Clinical Outcome 6 sex: ALL minimumAge: 17 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Alberta Children's Hospital city: Calgary state: Alberta country: Canada lat: 51.05011 lon: -114.08529 hasResults: False
nctId: NCT06300034 id: bagattoni2 briefTitle: Parental Perceptions and Acceptance of Silver Diamine Fluoride in Italy acronym: SDF overallStatus: COMPLETED date: 2020-09-01 date: 2022-02-01 date: 2022-03-01 date: 2024-03-08 date: 2024-03-08 name: University of Bologna class: OTHER briefSummary: Parental perceptions on staining due to Silver Diamine Fluoride (SDF) could affect its implementation in pediatric dentistry. This study represents the second part of a wider project focused on SDF aesthetic acceptability among Italian parents. conditions: Perceptions conditions: Acceptability conditions: SDF studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 234 type: ACTUAL measure: Parental overall acceptance of SDF staining on anterior and posterior teeth measure: Parental willingness to accept SDF treatment on anterior and posterior teeth depending on child's behavior measure: Parental overall acceptability of SDF staining according to demographic background sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Servizio di Assistenza Odontoiatrica per disabili in età evolutiva e di odontoiatria infantile city: Bologna country: Italy lat: 44.49381 lon: 11.33875 hasResults: False
nctId: NCT06300021 id: PEC19242 id: 2021-A00317-34 type: OTHER domain: ID-RCB briefTitle: Bioavailability of Curcuminoids From Turmipure Gold® in Different Food Matrices overallStatus: COMPLETED date: 2021-09-14 date: 2022-05-20 date: 2022-05-20 date: 2024-03-08 date: 2024-03-08 name: Givaudan France Naturals class: INDUSTRY name: BioFortis briefSummary: The goal of this clinical trial is to learn about the extent to which turmeric compounds in different food matrices becomes available to the body in healthy volunteers. The main question it aims to answer is:
Participants will ingest a turmeric dietary supplement as a capsule or in different food matrices on six testing days (separated by at least one week). The day before testing day, a standardized dinner will be provided to the participants in the evening and participants will be instructed to not consume any foods or beverages (except water) and to arrive fasted (12 hours) at the investigation site. Participants will ingest turmeric dietary supplement formulations one by one in random order in the morning of testing days. Regular blood and urine samples will be collected before and up to 24 hours after the turmeric dietary supplement ingestion. Standardized meals will be provided during the entire testing day (lunch, mid-afternoon snack, dinner). conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Monocentric, randomized, cross-over, open-label, pharmacokinetic study primaryPurpose: BASIC_SCIENCE masking: NONE count: 35 type: ACTUAL name: TPG capsule name: TPG ready to drink name: TPG dairy analog name: TPG probiotic drink name: TPG gummies name: TPG sport bar measure: Dose-normalized AUC0-24h of total curcuminoids measure: Dose-normalized AUC0-24h of curcuminoid compounds and of their metabolites measure: Dose-normalized AUC0-8h of total curcuminoids, curcuminoid compounds and of their metabolites measure: Dose-normalized AUC0-∞ of total curcuminoids, curcuminoid compounds and of their metabolites measure: AUC0-24h of total curcuminoids, curcuminoid compounds and of their metabolites measure: AUC0-8h of total curcuminoids, curcuminoid compounds and of their metabolites measure: AUC0-∞ of total curcuminoids, curcuminoid compounds and of their metabolites measure: Relative bioavailability for normalized AUC0-24h of total curcuminoids, curcuminoid compounds and of their metabolites measure: Relative bioavailability for normalized AUC0-8h of total curcuminoids, curcuminoid compounds and of their metabolites measure: Relative bioavailability for normalized AUC0-∞ of total curcuminoids, curcuminoid compounds and of their metabolites measure: Cmax of total curcuminoids, curcuminoid compounds and of their metabolites measure: Dose-normalized Cmax of total curcuminoids, curcuminoid compounds and of their metabolites measure: Half-life of total curcuminoids, curcuminoid compounds and of their metabolites measure: Tmax of total curcuminoids, curcuminoid compounds and of their metabolites sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Biofortis city: Saint-Herblain zip: 44800 country: France lat: 47.21765 lon: -1.64841 hasResults: False
nctId: NCT06300008 id: OrthoTU13 briefTitle: Cetylated Fatty Acid for Reducing Pain After TKA overallStatus: RECRUITING date: 2024-02-12 date: 2024-09 date: 2024-12 date: 2024-03-08 date: 2024-03-08 name: Thammasat University class: OTHER briefSummary: To compare efficacy of cetylated fatty acid with placebo for reducing postoperative pain after unilateral TKA. The hypothesis is topical cetylated fatty acid can mitigate postoperative pain after TKA. conditions: Postoperative Pain conditions: Postoperative Inflammation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: cetylated fatty acid name: Placebo measure: Visual analog scale measure: Visual analog scale measure: Visual analog scale measure: Visual analog scale measure: inflammatory marker measure: inflammatory marker measure: inflammatory marker measure: inflammatory marker measure: Knee skin temperature measure: Knee skin temperature measure: Knee skin temperature measure: Knee skin temperature measure: Knee circumference (cm) measure: Knee circumference (cm) measure: Knee circumference (cm) measure: Knee circumference (cm) measure: Knee Range of Motion measure: Knee Range of Motion measure: Knee Range of Motion measure: Knee Range of Motion measure: Modified WOMAC measure: Modified WOMAC measure: Modified WOMAC measure: Thai forgotten joint score measure: Thai forgotten joint score measure: Thai forgotten joint score sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: department of orthopaedic surgery, Faculty of medicine, Thammasat university status: RECRUITING city: Khlong Luang state: Pathumthani zip: 066 country: Thailand name: supakit kanitnate role: CONTACT phone: 6629260000 email: naypeng@hotmail.com name: Nattapol Tammachote, M.D. role: PRINCIPAL_INVESTIGATOR name: Supakit Kanitnate, M.D. role: SUB_INVESTIGATOR lat: 14.06467 lon: 100.64578 hasResults: False
nctId: NCT06299995 id: MFSP briefTitle: Phenotype and Burden of a Midfacial Segment Pain overallStatus: ENROLLING_BY_INVITATION date: 2024-02-24 date: 2025-03-31 date: 2025-03-31 date: 2024-03-08 date: 2024-03-19 name: Swiat Zdrowia class: OTHER briefSummary: The purpose of this study is to describe midfacial segment pain phenotype, burden and comorbidities in a multicentre and multidisciplinary setting. The ultimate goal is a comprehensive description of this type of pain allowing for its implementation in future classifications.
This cross-sectional study is designed to describe midfacial segment pain in a clinical setting. Patients from rhinologic, headache and facial pain or oral medicine/dentistry secondary care centres will be recruited during a one year period. Individuals with other facial pain according to current classification such as sinonasal disorders, neoplasms, local infections, history of significant trauma associated with pain onset will be excluded. Data will be collected through a structured questionnaire covering pain characteristics, coexisting diagnoses, pain-related burden and consequences, physical examination and paranasal sinuses imaging. conditions: Facial Pain studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED measure: Pain characteristics measure: Coexisting diagnoses measure: Pain-related burden and consequences sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Otolaryngology, University of Malta city: Imsida country: Malta lat: 35.8925 lon: 14.48278 facility: Athleticomed - Pain&Headache Treatment Centre city: Bydgoszcz country: Poland lat: 53.1235 lon: 18.00762 facility: Department of Otolaryngology, Head and Neck Surgery and Laryngological Oncology city: Bydgoszcz country: Poland lat: 53.1235 lon: 18.00762 facility: Department of Neurology, Jagiellonian University Medical College city: Kraków country: Poland lat: 50.06143 lon: 19.93658 facility: Świat Zdrowia city: Orzyny zip: 12-120 country: Poland lat: 53.67846 lon: 21.06617 facility: Department of Neurology and Restorative Medicine, Health Institute dr Boczarska-Jedynak city: Oświęcim country: Poland lat: 50.03437 lon: 19.21037 facility: 4. Department of Otorhinolaryngology, National Institute of Medicine of the Ministry of the Interior and Administration city: Warsaw country: Poland lat: 52.22977 lon: 21.01178 facility: 5. Department of Otolaryngology, Centre of Postgraduate Medical Education city: Warsaw country: Poland lat: 52.22977 lon: 21.01178 facility: Department of Experimental Dentistry, Wroclaw Medical University city: Wrocław country: Poland lat: 51.1 lon: 17.03333 facility: Department of Neurology, Wroclaw Medical University city: Wrocław country: Poland lat: 51.1 lon: 17.03333 facility: MIGRE Polish Migraine Center city: Wrocław country: Poland lat: 51.1 lon: 17.03333 facility: Pain Medicine, Liverpool University Hospitals NHS Foundation Trust city: Liverpool country: United Kingdom lat: 53.41058 lon: -2.97794 facility: Department of Otorhinolaryngology, Nottingham University Hospital city: Nottingham country: United Kingdom lat: 52.9536 lon: -1.15047 hasResults: False
nctId: NCT06299982 id: SSGJ-608-PsO-III-02 briefTitle: An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-01-30 date: 2025-03-20 date: 2024-03-08 date: 2024-03-08 name: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to examin the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis. conditions: Plaque Psoriasis Patients studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 750 type: ESTIMATED name: 608 Q2W name: 608 Q4W measure: Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) measure: Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement measure: Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) measure: Percentage of Participants Achieving a ≥100% Improvement in Psoriasis Area and Severity Index (PASI 100) measure: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) measure: Adverse events (AE) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299969 id: StBernwardH briefTitle: Feedback Intervention and Treatment Trial in Patients With Out-of-Hospital Cardiac Arrest acronym: FITT-OHCA overallStatus: RECRUITING date: 2023-01-01 date: 2025-12-31 date: 2025-12-31 date: 2024-03-08 date: 2024-03-08 name: St.Bernward Hospital class: OTHER name: University Medical Center Goettingen briefSummary: The trial collects and analyzes data from Cardiac Arrest Centres in patients with out-of-hospital cardiac arrest (OHCA). conditions: Out-Of-Hospital Cardiac Arrest studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 3000 type: ESTIMATED measure: In-hospital mortality measure: CPC score measure: MRS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St Bernward Hospital status: RECRUITING city: Hildesheim state: Niedersachsen zip: 31134 country: Germany name: Karl H Scholz, MD role: CONTACT phone: +4955139 phoneExt: 64940 email: k.scholz@fitt-stemi.de name: Sebastian Riedel role: CONTACT phone: +4955139 phoneExt: 64940 email: s.riedel@bernward-khs.de lat: 52.15077 lon: 9.95112 hasResults: False
nctId: NCT06299956 id: 2023-SFHHB-IC-001 briefTitle: Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark acronym: StRiDE overallStatus: RECRUITING date: 2023-09-01 date: 2029-01 date: 2029-01 date: 2024-03-08 date: 2024-03-21 name: Slagelse Hospital class: OTHER name: Region Zealand name: Vordingborg Municipality name: Kalundborg municipality name: Køge Municipality name: Næstved municipality name: Solrød Municipality briefSummary: The goal of this project is to implement a protocol for a supervised exercise therapy intervention including smoking cessation in the municipalities in region Zealand in Denmark. The participants are adults with intermittent claudication.
Participants will be asked to do supervised exercise therapy by walking on a treadmill for 3 times a week for 12 weeks, and engage in smoking cessation, if they are smoking. conditions: Intermittent Claudication studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 600 type: ESTIMATED name: Supervised exercise therapy measure: Maximal Walking Distance measure: Pain-free walking distance measure: Vascular Quality of Life Questionnaire-6 (VASCUQoL-6) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: PROgrez status: RECRUITING city: Slagelse zip: 4700 country: Denmark name: Helle Bøgard role: CONTACT email: hboga@regionsjaelland.dk name: Lars Tang role: CONTACT email: larta@reggionsjaelland.dk lat: 55.40276 lon: 11.35459 hasResults: False